Patricia Sinatra

Patricia has more than 25 years of experience in licensing, business development and strategy. She has led in- and out-licensing transactions, product acquisitions, portfolio assessments, and alliance management across a broad range of companies — spanning both full-time executive and interim leadership/ advisory support in the U.S. and China. Her therapeutic areas of expertise spans oncology, autoimmune/inflammation, infectious disease, metabolic disorders, and CNS, and she has worked across a variety of novel therapeutic modalities, including RNA and protein therapeutic approaches. Patricia has held positions of increasing responsibility for GSK, Fujisawa-SKF, Abgenix, Matrix (Chiron/Novartis), SEQUUS (ALZA/JNJ), Dynavax (Sanofi), and Sutro, reflecting a track record built across large pharma, biotech, and specialty settings. Her work has centered on novel technologies and platforms, with particular depth in deal structuring and strategic portfolio development, including, most recently, the applications of AI in developing RNA Therapeutics. An active contributor to the field’s professional community, Patricia has organized and served as a participating instructor for the BIO Business Development Fundamentals course since 2007. She has also served on educational committees focused on next-generation therapeutics and oncology. She also mentors through the UCSF entrepreneurship program. Patricia holds an undergraduate degree in biology from SUNY and completed post-graduate doctoral studies in microbiology at the University of Texas Southwestern Medical Center in Dallas.